Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
NCT05999084 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Conditions Studied
Interventions
- DRUG Anti-amyloid Monoclonal Antibodies (mAbs)
- COMBINATION_PRODUCT Standard of Care
Study Locations (8)
Georgia
- Georgia Memory Net Memory Assessment Clinic - Albany — Albany
- Georgia Memory Net Memory Assessment Clinic - Atlanta — Atlanta
- Emory Clinic — Atlanta
- Georgia Memory Net Memory Assessment Clinic - Augusta — Augusta
- Georgia Memory Net Memory Assessment Clinic - Gainesville — Gainesville
- Georgia Memory Net Memory Assessment Clinic - Macon — Macon
- Georgia Memory Net Memory Assessment Clinic - Savannah — Savannah
- Georgia Memory Net Memory Assessment Clinic - Vidalia — Vidalia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 735 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2028-07 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999084
The ClinicalTrials.gov registry entry for NCT05999084 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 735 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,434 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions — of which Anti-amyloid Monoclonal Antibodies (mAbs) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05999084 reports 8 study locations spanning 1 distinct geographic area — top geographies include Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05999084 about?
NCT05999084 is a clinical study titled "Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry". The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
What is the current status of trial NCT05999084?
This trial is currently recruiting. The enrollment target is 735 participants. The study started on 2025-03-06. Estimated completion is 2028-07.
What conditions does trial NCT05999084 study?
This clinical trial studies the following conditions: Alzheimer Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05999084?
The interventions under investigation include: Anti-amyloid Monoclonal Antibodies (mAbs) (DRUG), Standard of Care (COMBINATION_PRODUCT). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05999084?
This trial is sponsored by Emory University, which has 1,434 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05999084 being conducted?
This trial has 8 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.